Edition:
United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

0.32USD
6:49pm BST
Change (% chg)

$-0.61 (-65.72%)
Prev Close
$0.92
Open
$0.35
Day's High
$0.39
Day's Low
$0.31
Volume
1,761,984
Avg. Vol
153,907
52-wk High
$6.73
52-wk Low
$0.31

About

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)

Overall

Beta: 1.29
Market Cap(Mil.): $174.93
Shares Outstanding(Mil.): 30.00
Dividend: --
Yield (%): --

Financials

  CNAT.OQ Industry Sector
P/E (TTM): -- 69.29 32.55
EPS (TTM): -0.99 -- --
ROI: -53.65 8.90 13.82
ROE: -80.58 10.04 15.24

Conatus Pharma to explore options as liver disease drug fails trial

Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.

24 Jun 2019

UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial

June 24 Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.

24 Jun 2019

BRIEF-Conatus Says Top-Line Results From Encore-LF Clinical Trial Of Emricasan Did Not Meet Primary Endpoint

* CONATUS ANNOUNCES RESULTS FROM ENCORE-LF AND ENCORE-PH PHASE 2B CLINICAL TRIALS IN NASH CIRRHOSIS

24 Jun 2019

Conatus Pharma to explore options, liver disease drug fails trial

June 24 Conatus Pharmaceuticals Inc said on Monday it will cut staff by about 40% as part of a restructuring plan and explore options.

24 Jun 2019

BRIEF-Conatus Completes Enrollment In Phase 2B Clinical Trial Of Emricasan In Patients With Decompensated Nash Cirrhosis

* CONATUS ANNOUNCES COMPLETION OF ENROLLMENT IN ENCORE-LF PHASE 2B CLINICAL TRIAL OF EMRICASAN IN PATIENTS WITH DECOMPENSATED NASH CIRRHOSIS

12 Feb 2019

Earnings vs. Estimates